The state of biotech at time of innovation — and high prices
CAMBRIDGE, Mass. — We live in an age of miracles, but they come at a high cost, with new gene therapies costing millions of dollars each. Can we afford them? STAT senior writer Adam Feuerstein sat down with three industry CEOs to discuss this and other questions during a session called ‘The State of Biotech” at the inaugural STAT summit in Cambridge this week.
Dr. Athena Countouriotis, the president and chief executive officer of Turning Point Therapeutics (TPTX), spoke about the price Roche (RHHBY) set for a lung cancer drug, Rozlytrek. The drug currently costs about $17,050 per month; an earlier drug cost $15,000, while one competing drug, Vitrakvi, costs about twice as much.